文献速递糖尿病

胰高血糖素样肽-1受体激动剂与2型糖尿病不良脑血管结局风险:随机对照试验的系统综述与Meta分析

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本系统综述与Meta分析纳入28项随机对照试验共74148例2型糖尿病患者,评估胰高血糖素样肽-1受体激动剂(GLP-1RA)对不良脑血管结局的影响。结果显示GLP-1RA与安慰剂/活性对照相比显著降低不良脑血管结局风险(RR 0.83,95%CI 0.76-0.91;I²=0%),主要来自缺血性卒中及缺血性卒中/短暂性脑缺血发作复合终点的降低,出血性卒中无显著差异。

要点

  • GLP-1RA与安慰剂/活性对照相比降低不良脑血管结局风险(RR 0.83,95%CI 0.76-0.91;I²=0%)。
  • 心血管结局试验中GLP-1RA降低非致死性卒中风险(RR 0.85,95%CI 0.76-0.94),致死性卒中无显著差异。
  • GLP-1RA降低缺血性卒中(RR 0.73,95%CI 0.60-0.89)及缺血性卒中/TIA复合终点风险(RR 0.76,95%CI 0.65-0.90)。

核心结论

  • GLP-1RA,尤其是长效制剂,可减少2型糖尿病患者的缺血性脑血管事件。
  • 在2型糖尿病病程较短和基线eGFR较高的患者中观察到的获益显著更高。

研究设计与样本

  • 系统综述与随机对照试验Meta分析,检索PubMed、Embase、Web of Science、Cochrane Library及临床试验注册网站(PROSPERO:CRD42022331547)。
  • 纳入28项随机对照试验,共74148例2型糖尿病成人患者,治疗时长≥24周。
  • 采用固定效应模型计算风险比(RR),按个体药物、治疗时长和基线患者特征进行亚组分析,并使用GRADE框架评估证据质量。

主要发现

  • GLP-1RA与安慰剂/活性对照相比,不良脑血管结局风险显著降低(RR 0.83,95%CI 0.76-0.91;I²=0%)。
  • 汇总8项心血管结局试验数据,GLP-1RA与安慰剂相比降低非致死性卒中风险(RR 0.85,95%CI 0.76-0.94;I²=0%),致死性卒中无显著差异(RR 0.80,95%CI 0.61-1.05;I²=0%)。
  • GLP-1RA降低缺血性卒中风险(12项随机对照试验;RR 0.73,95%CI 0.60-0.89;I²=0%)及缺血性卒中/TIA复合终点风险(16项随机对照试验;RR 0.76,95%CI 0.65-0.90;I²=0%),出血性卒中无显著差异(3项随机对照试验;RR 0.92,95%CI 0.51-1.64;I²=0%)。
  • 治疗获益根据基线eGFR和糖尿病病程而不同(交互作用P<.1)。
  • 度拉糖肽、皮下/口服司美格鲁肽的获益具有统计学显著性(P<.05)。

局限性

  • 敏感性分析排除短效利司那肽后,消除了个体GLP-1RA效应之间的异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic/hemorrhagic stroke and transient ischemic attacks (TIA) in type 2 diabetes mellitus (T2DM) remains undetermined. OBJECTIVE: To pool effects of GLP-1RAs on adverse cerebrovascular outcomes and investigate impact of baseline variables on these effects. METHODS: PubMed, Embase, Web of Science, Cochrane Library, and clinical trial registry websites were searched for randomized controlled trials (RCTs) ≥24 weeks duration in adults with T2DM (PROSPERO: CRD42022331547). Adjudicated cerebrovascular events in GLP-1RA treatment vs control arms were pooled together to calculate risk ratios (RR) using fixed-effects model. Subgroup analysis was performed based on individual drugs, treatment duration, and baseline patient characteristics. Quality of evidence was assessed using GRADE framework. RESULTS: We identified 28 RCTs involving 74 148 patients (57% male; median [range], age 58 [52-67] years, BMI 32 [25.4-37.2] kg/m2, T2DM duration 9 [3.5-15.4] years, treatment duration 52 [24-259] weeks). GLP-1RA use in T2DM was associated with significantly decreased risk of adverse cerebrovascular outcomes vs placebo/active comparator (RR, 0.83; 95% CI, 0.76-0.91; I2 = 0%). Pooling data from cardiovascular outcome trials (n = 8), GLP-1RA treatment vs placebo was associated with reduced risk of nonfatal stroke (RR, 0.85; 95% CI, 0.76-0.94; I2 = 0%) but not fatal stroke (RR, 0.80; 95% CI, 0.61-1.05; I2 = 0%). GLP-1RA use was associated with reduced risk of ischemic stroke (RCTs = 12; RR, 0.73; 95% CI, 0.60-0.89; I2 = 0%), composite of ischemic stroke/TIA (RCTs = 16; RR, 0.76; 95% CI, 0.65-0.90; I2 = 0%), but not hemorrhagic stroke (RCTs = 3; RR, 0.92; 95% CI, 0.51-1.64; I2 = 0%). Treatment benefits differed according to baseline eGFR and diabetes duration (P interaction < .1). Benefits were statistically significant for dulaglutide, subcutaneous/oral semaglutide (P < .05). Sensitivity analysis, excluding shorter-acting lixisenatide, eliminated the heterogeneity between individual GLP-1RA effects. CONCLUSION: GLP-1RAs, particularly longer-acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Banerjee M, Pal R, Mukhopadhyay S, et al. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2023. PMID: 36800286. doi:10.1210/clinem/dgad076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。